Tag: Concert Pharmaceuticals

Concert Pharma Announced the Initiation of Early-Stage Schizophrenia Study

Concert Pharmaceuticals, Inc. CNCE announced that it has initiated a multiple-ascending dose ("MAD") phase I study on its pipeline candidate, CTP-692 (a novel deuterium-modified form of D-serine), as ...